Syon Capital’s Vir Biotechnology VIR Stock Holding History

Syon Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,534	Closed	-$77.3K	–	662
2024 Q4	$77.3K	Buy	+10,534	New	+$83.1K	0.01%	555

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Syon Capital's VIR Position: Q1 2025 in Review

Syon Capital sold out of Vir Biotechnology (VIR) in Q1 2025, closing a stake of 10,534 shares — an estimated $77.3K sold.

Syon Capital first reported a position in VIR in Q4 2024 and held it in 1 quarter. The position peaked at $77.3K in Q4 2024. 233 funds tracked by Wall St. Rank hold VIR as of Q1 2025.

Syon Capital reported no remaining Vir Biotechnology position as of Q1 2025 after selling out during the quarter.
Syon Capital sold 10,534 Vir Biotechnology shares in Q1 2025, an estimated $77.3K.
Syon Capital first reported a position in Vir Biotechnology in Q4 2024 and held it in 1 quarter.
Syon Capital's Vir Biotechnology position peaked at $77.3K in Q4 2024.
233 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2025.

Based on Syon Capital's 13F filing for Q1 2025, filed 15 May 2025.